Guangdong Annuo Pharmaceutical Co., Ltd.

Primary Objective: To investigate the pharmacokinetics of a single oral dose of the test formulation, esomeprazole enteric-coated tablets (5 mg, provided by Guangdong Annoroad Pharmaceutical Co., Ltd.), and the reference formulation, esomeprazole enteric-coated tablets (Yilian®, 5 mg, certified by Livzon Pharmaceutical Factory, Livzon Group), in healthy adult subjects under both fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations under fasting and postprandial administration. Secondary Objective: To investigate the safety of the test formulation, esomeprazole enteric-coated tablets, and the reference formulation, esomeprazole enteric-coated tablets (Yilian®), in healthy adult subjects.

Primary Study Objective: This study used fluvastatin sodium extended-release tablets (80 mg, calculated as C₂₄H₂₆FNO₄) produced by Guangdong Annuo Pharmaceutical Co., Ltd. as the test formulation. In accordance with relevant bioequivalence regulations, fluvastatin sodium extended-release tablets (80 mg, owned and produced by Beijing Novartis Pharmaceuticals Co., Ltd.) served as the reference formulation. The study aimed to evaluate the bioequivalence of the test and reference formulations after administration under fasting and fed conditions. Secondary Study Objective: To observe the safety of the test and reference formulations, fluvastatin sodium extended-release tablets, in healthy volunteers.

The purpose of this study is to use indapamide tablets provided by Guangdong Annuo Pharmaceutical Co., Ltd. as the test preparation, and conduct human bioavailability and bioequivalence tests with indapamide tablets (Na-Cai Li) produced by Les Laboratoires Servier in accordance with the relevant provisions of bioequivalence tests. During the study, the safety and tolerability of indapamide tablets were evaluated by changes in adverse event rates, laboratory test results, vital signs, and physical examinations.